Welcome to our dedicated page for Cyclerion Therapeutics news (Ticker: CYCN), a resource for investors and traders seeking the latest updates and insights on Cyclerion Therapeutics stock.
Cyclerion Therapeutics, Inc. (CYCN) is a Nasdaq-listed clinical-stage biopharmaceutical company that provides frequent updates on its progress in neuropsychiatric drug development and the monetization of its legacy soluble guanylate cyclase (sGC) portfolio. This news page aggregates company press releases and market-moving announcements so readers can follow how Cyclerion’s strategy and pipeline evolve over time.
Recent news highlights Cyclerion’s transformation into a neuropsychiatric company, centered on an individualized therapy for treatment-resistant depression (TRD). The company has reported a license agreement with the Massachusetts Institute of Technology for technology to treat neuropsychiatric disorders and has announced CYC-126, an anesthetic-based investigational therapy that uses real-time EEG monitoring and algorithm-guided dosing, as its lead program for TRD.
Investors and observers can also track Cyclerion’s collaboration and business development activity. Updates include an application-specific, exclusive collaboration with Medsteer SAS to integrate closed-loop anesthetic delivery technology into CYC-126, as well as agreements to sell or license legacy sGC assets such as zagociguat, CY3018, praliciguat, and olinciguat. These items illustrate how the company aims to generate non-dilutive funding while building its neuropsychiatric pipeline.
In addition, the news flow covers corporate governance and capital markets developments, including board appointments, leadership changes, reverse stock split actions, and Nasdaq listing compliance updates. By reviewing this page regularly, readers can follow Cyclerion’s clinical plans, partnership announcements, licensing milestones, and strategic updates that may influence the CYCN stock narrative.
Cyclerion Therapeutics announced that its management will present a corporate overview at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 4:00 p.m. ET. Investors can request individual meetings through Jefferies. The presentation will be accessible via the Investors & Media section of the Cyclerion website, and an archived replay will be available for 90 days post-event.
Cyclerion is focused on developing treatments to restore cognitive function, with its lead compound CY6463 currently in clinical trials for Alzheimer's Disease and other cognitive impairments.
Cyclerion Therapeutics has made significant strides in its development strategies for CY6463, a CNS-penetrant sGC stimulator, receiving FDA IND clearance for Alzheimer's Disease with vascular pathology (ADv) and advancing its MELAS program. The company plans to initiate a clinical trial for ADv by mid-2021. Additionally, a new clinical program for cognitive impairment associated with schizophrenia (CIAS) was introduced with insights from Dr. Andreas Reif. Cyclerion also announced CY3018, a next-generation sGC stimulator, aiming to enhance CNS treatment.
Cyclerion Therapeutics announces the appointment of Dr. Errol De Souza to its board of directors, effective April 26, 2021. Dr. De Souza brings extensive experience in CNS drug development and has held leadership roles in various biotech firms. His expertise is expected to provide strategic guidance for Cyclerion's mission to restore cognitive function through innovative treatments. The company’s lead molecule, CY6463, is currently in clinical trials for cognitive impairment conditions, including Alzheimer’s Disease with vascular pathology and MELAS.
Cyclerion Therapeutics (Nasdaq: CYCN) announces that COO Cheryl Gault will present a corporate overview at B. Riley’s Neuroscience Investor Conference on April 29, 2021, at 1:00 p.m. ET. Attendees can also engage in one-on-one meetings with Cyclerion leaders at the event. The live webcast will be available on the Cyclerion website, along with an archived replay for 90 days. The company is focused on developing treatments to restore cognitive function, with its lead molecule, CY6463, currently in clinical development for Alzheimer's Disease with Vascular pathology and MELAS.
Cyclerion Therapeutics will host a webinar on April 27 at 8 a.m. EDT to discuss clinical updates for its CNS penetrant sGC stimulator, CY6463, focusing on its potential in treating Alzheimer's Disease with Vascular pathology (ADv) and Mitochondrial Encephalomyopathy (MELAS). Key opinion leader Andreas Reif, M.D. will discuss the sGC pathway's role in Cognitive Impairment Associated with Schizophrenia (CIAS). Cyclerion will also introduce a new candidate, CY3018, as part of their commitment to restore cognitive function.
TransMedics Group appointed Stephanie Lovell to its Board of Directors and the Nominating and Corporate Governance Committee, effective March 22, 2021. With over 30 years of experience in healthcare management and legal affairs, she currently serves as Executive Vice President and Chief Legal Officer for Blue Cross Blue Shield of Massachusetts. Lovell's expertise is expected to enhance TransMedics' strategy in the U.S. transplant market. The company aims to improve organ transplantation outcomes through innovative technologies that increase donor organ utilization.
Cyclerion Therapeutics (Nasdaq: CYCN) announced the resignation of Chief Medical Officer Christopher Wright, M.D., Ph.D., effective March 26, 2021. He will transition to a role on the Clinical Advisory Board, continuing to support the company. CEO Peter Hecht acknowledged Wright's contributions to clinical efforts. Cyclerion is focused on developing treatments for cognitive function, with its leading candidate, CY6463, showing promising results in clinical trials for Alzheimer's Disease with vascular pathology and MELAS.
Cyclerion Therapeutics (CYCN) reported its 2020 financial results and corporate updates, emphasizing the promising data from its lead asset, CY6463. The Phase 1 study confirmed favorable safety and blood-brain barrier penetration with improvements in cognitive biomarkers. The company announced upcoming Phase 2a trials for Alzheimer’s disease with vascular pathology and MELAS. Despite a net loss of approximately $77.8 million for 2020, Cyclerion expects reduced operating costs in 2021 from organizational changes, including a $10 million savings from exiting current facilities.
Cyclerion Therapeutics (Nasdaq: CYCN) announced the formation of clinical and scientific advisory boards to advance its therapeutic pipeline, particularly focusing on CY6463, a CNS-penetrant sGC stimulator targeting cognitive impairment. The new advisory boards consist of prominent experts in CNS diseases and therapeutic development, with a goal to optimize the company's development path. CY6463 is currently under clinical investigation for Alzheimer's Disease with Vascular pathology (ADv) and Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS).
Cyclerion Therapeutics (Nasdaq: CYCN) announced its participation in two upcoming investor conferences. The company will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 3:40 p.m. ET, with a webcast available on their website. Additionally, an on-demand presentation will be available at the H.C. Wainwright BioConnect Conference on January 11, 2021, at 6:00 a.m. ET. Cyclerion focuses on innovative treatments for serious CNS diseases, notably their lead program, CY6463, aimed at conditions like MELAS and Alzheimer's with vascular pathology.
FAQ
What is the current stock price of Cyclerion Therapeutics (CYCN)?
What is the market cap of Cyclerion Therapeutics (CYCN)?
